In the first quarter of 2024, Dupixent generated global product sales of $3.09 billion (€2.84 billion), which were recorded by Sanofi, representing growth of 24.9% at a constant exchange rate.

Dupixent is a key top-line driver for Sanofi and Regeneron. During first-half 2024, Sanofi recorded €6.14 billion from Dupixent product sales, indicating 27% year-over-year growth.

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use of Dupixent ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program.

Dupixent: A Key Top-Line Driver for SNY Sanofi’s immunology drug, Dupixent has become the key top-line driver as it enjoys strong demand across all approved indications and geographies.

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat estimates, reaching €13.44 billion, up 12.3%.

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.

Sales of Dupixent, which is approved to treat conditions such as asthma and eczema, rose 29.2% to 3.30 billion euros ($3.57 billion), above the 3.18 billion euro expected on average by analysts in ...

Sanofi markets and sells >30 major drug products, although only two drugs, Dupixent and the company's polio / pertussis shot, earned >$1bn in revenues in the first half of 2024.

Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.